NMN zwitterion/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60.”
Quoted verbatim from The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.. - Study
- RCT
- Duration
- 2 months
- Dose
- 300, 600 or 900 mg NMN once daily orally for 60 days
- Population
- Healthy middle-aged adults in a randomized, multicenter, double-blind, placebo-controlled, parallel-group trial; 300, 600 and 900 mg NMN groups each compared with placebo at day 60
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.2023PMID:36482258Permalink
Keep reading
- Everything the graph holds on NMN zwitterion
- Every compound studied against HOMA-IR
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PNGGJY2WDKT0YGR8CE33X0